Previous close | 0.3605 |
Open | 0.3600 |
Bid | 0.3665 x 1080000 |
Ask | 0.3755 x 1250000 |
Day's range | 0.3600 - 0.3715 |
52-week range | 0.3600 - 1.2235 |
Volume | |
Avg. volume | 555 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 12 July 2023 - 17 July 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
TORONTO, May 25, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has reached agreement with Phylos Bioscience Inc. ("Phylos"), a U.S. cannabis genetics company and provider of production ready seeds, based in Portland, Oregon, to initiate a wide-ranging technical and commercial relationship in Canada. This innovation relationship is expected to further support Organigram’s industry leading
TORONTO, May 23, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce today that it has entered into a supply agreement ("the Agreement") for dried flower with the medical division of German cannabis company Sanity Group, a health and life sciences company based in Berlin, Germany, dedicated to the medical applications of cannabinoids. Through exports from its flagship state-of-the-art cultivatio
TORONTO, May 20, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that its wholly-owned subsidiary, The Edibles and Infusions Corporation ("EIC") has met certain of the remaining earnout milestones that formed part of the terms of its acquisition in April, 2021.
Organigram (TSX: OGI) stock is seeing big sell-offs in Wednesday's trading. Organigram published results for the second fiscal quarter after the market closed yesterday, and sales in the period fell significantly short of the market's expectations. While revenue in the period increased roughly 24% year over year to reach 39.5 million Canadian dollars, the average analyst estimate had called for sales of CA$43.6 million, and the shortfall has contributed to a big pullback for the stock.
OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, April 11, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the second quarter ended February 28, 2023 ("Q2 Fiscal 2023"). All financial information in this press release is expressed in thousands of Canadian dollars ("$"), except for references to $ millions.
Tilray Brands (NASDAQ: TLRY) shook up the cannabis sector with its third-quarter fiscal 2023 earnings report last night. As of 11:15 a.m. ET, Tilray shares were lower by 7.1%, while Hexo stock was plunging by 26.5%. The moves were spurred by the announcement of a deal for Tilray to acquire Hexo in an all-stock transaction.
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Shares of the craft cannabis company Organigram Holdings (NASDAQ: OGI) were up by 5.98% on heavy volume as of 2:49 p.m. ET Monday afternoon. Organigram and fellow Canadian pot titan Tilray Brands (NASDAQ: TLRY) are both set to report their latest fiscal results this week. While Tilray will report its fiscal 2023 Q3 earnings after market close today, Organigram is scheduled to reveal its fiscal 2023 Q2 earnings after the closing bell on Tuesday.
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
TORONTO, April 04, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2023 ended February 28, 2023, on Tuesday, April 11, 2023, after market close.
TORONTO, March 31, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it has entered into a product purchase agreement ("Purchase Agreement") with Green Tank Technologies Corp. ("Greentank") a leading vaporization technology company and a subscription agreement ("Subscription Agreement") with Greentank’s parent company, Weekend Holdings Corp ("Holdings").
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.
TORONTO, March 21, 2023--Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI; NASDAQ: OGI), announced that BAT has designated Ms. Caroline Ferland as a nominee to Organigram’s board of directors (the "Board"). Caroline Ferland is a lawyer with extensive international experience assisting multinational companies to operate with confidence and integrity in highly regulated and high-risk environments. As the first Group Head of Business Conduct and Compliance for BAT, Caroline led th
TORONTO, March 13, 2023--Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI; NASDAQ: OGI), announced that it has received notification from Health Canada that Health Canada has determined that certain Jolts lozenge products in their 100 mg THC per package format (the "Products") have been improperly classified as an "extract" rather than an "edible" under the Cannabis Regulations. The Company launched the Products in August 2021 following significant research, development and reg
Investors in cannabis companies should know they're playing a long game. The multi-state operator (MSO) has seen its shares drop 35% over the past year, and that fall has continued with a 9% decline so far in 2023.
TORONTO, March 01, 2023--Organigram Holdings Inc. ("Organigram" or the "Corporation") (TSX: OGI) (NASDAQ: OGI) announced today the results of voting at its annual general and special meeting of shareholders held on February 28, 2023 (the "Meeting").
TORONTO, February 27, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the launch of SHRED X Rip-Strip Hash, a first-of-its-kind innovation in the Canadian cannabis industry. This botanical terpene-infused hash is unlike any other on the market – with 10 pre-cut strips of hash available in a 2g format. This product is a new ultra-convenient hash offering from SHRED that is available in the le
TORONTO, January 26, 2023--Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI; NASDAQ: OGI), today announced that it received notification (the "Notification") from The Nasdaq Stock Market LLC ("NASDAQ") that it is not in compliance with the minimum bid price requirement in NASDAQ Listing Rule 5450(a)(1) for continued listing on the NASDAQ Global Select Market, since the closing bid price for the Company’s common shares listed on NASDAQ was below US$1.00 for 30 consecutive tradin
It can be hard for investors to see anything good in the cannabis space through all the smoke of 2022's collapsing share prices. Thanks to the market's general malaise regarding the industry, at least three are selling at discounts and look likely to be great long-term holdings over the next decade: Trulieve Cannabis (OTC: TCNNF), NewLake Capital Partners (OTC: NLCP) and OrganiGram Holdings (NASDAQ: OGI). All three cannabis companies are trading at price-to-book ratios below what their assets would bring if sold off, and at lower ratios than other large cannabis companies such as Canopy Growth and Curaleaf Holdings.
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, January 12, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the first quarter ended November 30, 2022 ("Q1 Fiscal 2023"). All financial information in this press release is expressed in thousands of Canadian dollars ("$"), except for references to $ millions.
TORONTO, January 05, 2023--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2023 ended November 30, 2022, on Thursday, January 12, 2023, before market open.
OrganiGram (OGI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.